Family practice patients’ use of acetylsalicylic acid for cardiovascular disease prevention – Forum

Date: 2013-04-06

Reference number: OPUSeJ 201304061946ASA

Links: to published article:

to cover page:

Title: Family practice patients’ use of acetylsalicylic acid for cardiovascular disease prevention

Authors: Michael Kolber, Nadder Sharif, Raelene Marceau and Olga SzafranModerator: N/A

Overview: N/A

Addendum: none

Erratum: none

Bibliography: (alphabetical) N/A


Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH. Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. Am J Prev Med 2006;30(1):74-7.

Pignone M, Anderson GK, Binns K, Tilson HH, Weisman SM. Aspirin use among adults aged 40 and older in the United States: results of a national survey. Am J Prev Med 2007;32(5):403-7.

Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med 2008; 121(1):43-9.

Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329):71-86. Erratum in: BMJ 2002;324 (7330):141.

Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295(3):306-13. Erratum in: JAMA 2006;295 (17):2002.

Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352(13):1293-304. Epub 2005 Mar 7.

Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373(9678):1849-60.

Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 150(6):405-10.

Sørensen HT, Mellemkjaer L, Blot WJ, Nielsen GL, Steffensen FH, McLaughlin JK, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000;95(9):2218-24.

De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009;339:b4531.DOI:.

Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003;26(12):3264-72.

Walsh M, Spurling G. Aspirin in type 2 diabetes: is there any evidence base? BMJ 2008;337:a1902.DOI:.

Lip GY, Felmeden DC. Antiplatelet agents and anticoagulants for hypertension. Cochrane Database Syst Rev 2004;(3):003186.

Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300(18):2134-41. Epub 2008 Nov 9.

Statistics Canada [website]. 2006 Community profiles. Peace River, Alberta. Catalogue no. 92-591-XWE. Ottawa, ON: Statistics Canada; 2010.

Centers for Disease Control and Prevention. 2003 Behavioral risk factor surveillance system state questionnaire. Atlanta, GA: Centers for Disease Control and Prevention; 2002.

Statistics Canada [website]. Canada’s population estimates. Population by sex and age group. Ottawa, ON: Statistics Canada; 2010.

Friedmann PD, Brett AS, Mayo-Smith MF. Differences in generalists’ and cardiologists’ perceptions of cardiovascular risk and the outcomes of preventive therapy in cardiovascular disease. Ann Intern Med 1996;124(4):414-21.

Frijling BD, Lobo CM, Keus IM, Jenks KM, Akkermans RP, Hulscher ME, et al. Perceptions of cardiovascular risk among patients with hypertension or diabetes. Patient Educ Couns 2004;52(1):47-53.

Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989;321(3):129-35.

Patrono C, Baigent C, Hirsh J, Roth G. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133(6 Suppl):199S-233S.

Tsuyuki RT, Koshman S, Pearson G. Guideline for management of modifiable risk factors in adults at high risk for cardiovascular events. Edmonton, AB: Toward Optimized Practice; 2009.

Guidelines & Protocols Advisory Committee. Cardiovascular disease— primary prevention. Vancouver, BC: British Columbia Medical Association; 2008.

Public Health Agency of Canada. Tracking heart disease and stroke in Canada. Ottawa, ON: Public Health Agency of Canada; 2009.

Laine L. Review article: gastrointestinal bleeding with low-dose aspirin— what’s the risk? Aliment Pharmacol Ther 2006;24(6):897-908.

Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000;321(7270):1183-7.

Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329(7456):15-9.

Allan GM, Kolber MR. ASA in primary prevention: do the benefits outweigh risks? Edmonton, AB: Alberta College of Family Physicians; 2009.

Kolber MR, Wong CWK. Acetylsalicylic acid (ASA) to prevent colorectal cancer? Edmonton, AB: Alberta College of Family Physicians; 2011.

Brown LC, Johnson JA, Majumdar SR, Tsuyuki RT, McAlister FA. Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ 2004;171(10):1189-92.

Alter DA, Khaykin Y, Austin PC, Tu JV, Hux JE. Processes and outcomes of care for diabetic acute myocardial infarction patients in Ontario: do physicians undertreat? Diabetes Care 2003;26(5):1427-34.

Grimaldi-Bensouda L, Rossignol M, Aubrun E, El Kerri N, Benichou J, Abenhaim L, et al. Agreement between patients’ self-report and physicians’ prescriptions on cardiovascular drug exposure: the PGRx database experience. Pharmacoepidemiol Drug Saf 2010;19(6):591-5. Erratum in: Pharmacoepidemiol Drug Saf 2010;19 (11):1209.

Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ. Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol 2004;57(10):1096-103.

Citation: Kolber, M et al, 2013, “Family practice patients’ use of acetylsalicylic acid for cardiovascular disease prevention”, Canadian Family Physician 59:1, 55-61.

Academic citations forward: none

Other citations forward: none

Leave a Reply